Cellectis SA (CLLS) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Cellectis SA is showcasing its innovative strategies to improve the effectiveness of CAR T-cell therapies against solid tumors at the Society for Immunotherapy of Cancer’s Annual Meeting. By using TALEN-mediated gene editing, Cellectis aims to enhance the efficacy of these therapies while minimizing potential toxicities, offering hope for patients with challenging malignancies. This development underscores the company’s commitment to advancing cancer treatment with cutting-edge biotechnology.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.
